CAPOTEN

Compare CAPOTEN  to:
Compare
Compare

Generic Name for CAPOTEN

Captopril 12.5mg, 25mg, 50mg, 100mg; scored tabs.

Legal Classification:

Rx

Pharmacological Class for CAPOTEN

ACE inhibitor.

Manufacturer of CAPOTEN

Par Pharmaceutical, Inc.

Indications for CAPOTEN

Hypertension.

Adult dose for CAPOTEN

Take 1 hr before meals. Initially 25mg 2–3 times daily. After 1–2 wks may increase to 50mg 2–3 times daily. If control unsatisfactory, see literature. Titrate to usual dose after several days. Monitor closely for 1st 2 wks and if dose increased; max 450mg/day. Renal impairment: see literature.

Children's dosing for CAPOTEN

See literature.

Contraindications for CAPOTEN

History of ACEI-associated or other angioedema. Pregnancy (Cat.D in 2nd and 3rd trimesters).

Warnings/Precautions for CAPOTEN

Renal impairment. Salt/volume depletion. CHF. Dialysis (esp. high-flux membrane). Aortic stenosis. Monitor WBCs and renal function in renal and collagen vascular disease. Monitor for hyperkalemia in diabetics and renal insufficiency. Surgery. Discontinue if neutropenia, agranulocytosis, angioedema, or laryngeal edema occurs. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended.

Interactions for CAPOTEN

Caution with K+-sparing diuretics and K+-containing supplements. May be antagonized by NSAIDs. Potentiated by diuretics, β-blockers, adrenergic antagonists. May increase lithium levels. May produce false (+) urinary acetone.

Adverse Reactions for CAPOTEN

Headache, dysgeusia, rash, pruritus, dizziness, fatigue, cough, proteinuria, nephritis, GI upset, hyperkalemia, hyponatremia, back pain, tachycardia, dry mouth, jaundice, somnolence, sweating, sinusitis, impotence, angioedema.

How is CAPOTEN supplied?

Tabs 25mg, 50mg—100, 1000
12.5mg, 100mg—100

Related Disease:

Hypertension

Related Resources

Tekamlo approved for hypertension

August 27, 2010

The FDA has approved Tekamlo (aliskiren and amlodipine tablets, from Novartis), a single, combination therapy tablet for the treatment of hypertension, alone or with other antihypertensive agents.

Tribenzor approved for treatment of hypertension

July 26, 2010

Daiichi Sankyo announced that the FDA has approved Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide tablets), a fixed-dose combination therapy for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers, and diuretics.

FDA warns of dangerous ingredients in Joyful Slim herb supplement

July 22, 2010

The FDA is warning consumers that Joyful Slim herb supplement, marketed as a natural herb for weight loss, contains undeclared desmethyl sibutramine, an FDA-approved drug used as an appetite suppressant for weight loss.

FDA conducts safety review of cancer risk with angiotensin receptor blockers (ARBs)

July 15, 2010

A recently published meta-analysis combining cancer-related findings from several clinical trials is suggesting that angiotensin receptor blockers (ARBs) may be associated with a small increased risk of cancer.

FDA reviews cardiovascular mortality risk associated with Benicar

June 11, 2010

The FDA is evaluating data from two clinical trials in which patients with type 2 diabetes taking Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) had a higher rate of death from a cardiovascular cause compared to patients taking a placebo.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions